Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
The latest announcement is out from Entero Therapeutics ( (ENTO) ).
On February 3, 2025, Entero Therapeutics announced a significant restructuring of its Board of Directors. The company appointed Manpreet Uppal, Alson Niu, and Richard Joel Paolone as new directors, replacing Timothy Ramdeen, Alastair Riddell, and James Sapirstein. However, on February 5, 2025, Alson Niu resigned and was replaced by Eric Corbett. These changes are expected to impact the company’s governance structure, with the new directors bringing diverse expertise in capital markets, corporate finance, and legal matters.
More about Entero Therapeutics
YTD Price Performance: -15.38%
Average Trading Volume: 202,419
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $2.61M
For detailed information about ENTO stock, go to TipRanks’ Stock Analysis page.